Identifying targets for diagnosis, prognosis, and treatment

This issue of Neurology® Neuroimmunology & Neuroinflammation (N2) incorporates exciting studies on the biology of immunologic and inflammatory biomarkers and the importance of knowing the benefits and complications of targeted therapies. In addition, the issue includes several clinically relevant reports on viral and autoimmune encephalitis. The concept of precision medicine, recently re-enhanced by public media, is not new in clinical and basic research. An interesting example is the case presented by Euskirchen et al. of a patient with life-threatening brainstem neurohistiocytosis in the context of Erdheim-Chester disease and cutaneous Langerhans cell histiocytosis. Detection of a BRAF mutation in affected tissues led to the selection of a specific BRAF inhibitor (vemurafenib), resulting in a rapid clinical response. On the other hand, Kornberg et al. suggest that the use of targeted therapies in an inappropriate context, such as fingolimod and natalizumab in neuromyelitis optica (NMO) instead of multiple sclerosis (MS), carries the risk of disease exacerbation. The authors postulate that a combination of drug effects, including an increase of blood-brain barrier permeability allowing CNS entry of Th17 lymphocytes, was responsible for the clinical worsening in the case they present. In another report, Hillen et al. postulate that natalizumab may have contributed to fulminant liver failure related to hepatitis B infection in a patient receiving the drug for relapsing-remitting MS (RRMS). Svenningsson et al. show that rituximab, a drug used for both MS and NMO, rapidly distributes to the peripheral compartment following intrathecal administration. Ultralow doses of intrathecal rituximab were sufficient to cause complete and prolonged depletion of B lymphocytes in both the CNS and systemic compartments, an observation with potential implications for other disorders, such as autoimmune encephalitis. Three additional studies use immunologic cells or autoantibodies as biomarkers of disease or treatment outcome. In a study of children with a first episode of acquired demyelinating syndrome, Hacohen et al. found that the presence of myelin oligodendrocyte glycoprotein (MOG) antibodies at symptom onset predicted a non-MS disease course. These findings confirm previous studies indicating that patients with optic neuritis and MOG antibodies have a low probability of developing MS or NMO. De Raedt et al. describe that the detection of a high circulating natural killer (NK) cell count within the first hours after an acute ischemic stroke, followed by a drop in all lymphocyte subsets, identifies patients prone to develop infections, likely as a result of autonomic dysfunction with sympathetic overdrive. Elkins et al. investigated the relationship between CD56 NK cells and disease activity in patients with RRMS treated with daclizumab high-yield process (DAC HYP). In this preliminary study, the authors found a statistically significant inverse relationship between CD56 NK cell counts measured after DAC HYP and the number of new or enlarged T2-hyperintense lesions that developed between weeks 24 and 52 posttreatment. The findings, which need validation in prospective studies, suggest that CD56 NK cell counts should be considered as a potential surrogate to understanding individual variation in the treatment response to DAC HYP. A study by Bar-Or et al. provides Class II evidence that in normal subjects treated with teriflunomide (a drug used in RRMS that blocks pyrimidine synthesis), antibody titer responses to rabies vaccination are lower than with placebo but sufficient for seroprotection. The findings support the view that teriflunomide decreases autoaggressive immune responses in MS but does not limit the ability to mount primary adaptive humoral immune responses or alter delayed T-cell hypersensitivity. The work of Guptill et al. shows that patients with musclespecific tyrosine kinase myasthenia gravis have higher plasma B cell–activating factor levels and lower percentages of B10 cells than healthy controls. The authors suggest that the reduction of regulatory B10 cells, which produce the anti-inflammatory cytokine interleukin (IL)-10, likely explains a previously reported increase of proinflammatory Th1 and Th17